| Principle Investigator | Study Sponsor | Title (click for details) |
| Haifaa Abdulhaq, MD | University of California, San Francisco | Improving Survivorship Care for Older Adults After Chemotherapy |
| Haifaa Abdulhaq, MD | Millennium Pharmaceuticals, Inc. | A Randomized, Open-Label, Phase 3 Trial of A+AVD vs. ABVD as Frontline Therapy in Patients with Advanced Classical Hodgkin Lymphoma |
| Haifaa Abdulhaq, MD | National Cancer Institute (NCI) | A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)” (NCT # NCT03737981) |
| Haifaa Abdulhaq, MD | National Cancer Institute (NCI) | Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas |
| Haifaa Abdulhaq, MD | National Cancer Institute (NCI) | A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL negative B lineage Acute Lymphoblastic Leukemia in Adults |
| Haifaa Abdulhaq, MD | National Cancer Institute (NCI) | A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults |
| Haifaa Abdulhaq, MD | Epizyme, Inc | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma |
| Haifaa Abdulhaq, MD | University of California, Davis | Investigation of MRD in the Blood Measured by High Throughput Sequencing of T Cell Receptor Clonal Frequency in Patients with Treatment-Naïve Systemic T Cell Lymphoma Treated with a Brentuximab-Containing Regimen – A Pilot Study |
| Haifaa Abdulhaq, MD | Hoffman-LaRoche Ltd. | A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Glofitamab in Combination With Gemcitabine Plus Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
| Haifaa Abdulhaq, MD | University of California, Davis | A Phase II Trial of the Combination of Obinutuzumab, Ibrutinib, and Venetoclax in Patients With Previously Untreated Follicular Lymphoma |
| Haifaa Abdulhaq, MD | Pfizer C1071005 | AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR |
| Haifaa Abdulhaq, MD | Novartis Pharmaceuticals Corporation | A Phase II multicenter, open-label, single-arm dose escalation study of Asciminib monotherapy in 2nd and 1st Line Chronic Phase - Chronic Myelogenous Leukemia (ASC2ESCALATE) |
| Haifaa Abdulhaq, MD | Celgene Corporation | A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-Naive Participants Who Are Non-Transfusion Dependent (NTD): The "ELEMENT-MDS" Trial |
| Haifaa Abdulhaq, MD | Hoffman-LaRoche Ltd. | A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma |
| Haifaa Abdulhaq, MD | University of California, Davis | A Phase 2 Study of Loncastuximab Tesirine and Rituximab (Lonca-R) followed by DA-EPOCH-R in Previously Untreated High-Risk Diffuse Large B-cell Lymphoma |
| Haifaa Abdulhaq, MD | BeOne Medicines, Ltd. | Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma |
| Haifaa Abdulhaq, MD | Incyte Corporation | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) |
| Haifaa Abdulhaq, MD | ADC Therapeutics Sarl | A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) |
| Haifaa Abdulhaq, MD | Pfizer C1071032 | A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY |
| Haifaa Abdulhaq, MD | Acrotech Biopharma LLC | SPI-BEL-301: A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients with Peripheral T-Cell Lymphoma |
| Haifaa Abdulhaq, MD | Janssen Research & Development, a J&J Co | 64407564MMY3009 A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (TalTec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide |
| Haifaa Abdulhaq, MD | Janssen Research & Development, a J&J Co | 64007957MMY3005 A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy |
| Haifaa Abdulhaq, MD | | Retrospective Review of Patients Diagnosed with Plasma Cell Leukemia Treated Within the University of California Hematologic Malignancies Consortium |
| Haifaa Abdulhaq, MD | Iterion Therapeutics | Tegavivint (BC2059) Single Patient Compassionate Use Protocol |
| Haifaa Abdulhaq, MD | | Managed Access Program (MAP) Cohort Treatment Plan CCTL019B2003I to provide access for patients with out of specification leukapheresis product and/or out of specification manufactured tisagenlecleucel (CTL019; Kymriah®) |
| Haifaa Abdulhaq, MD | | Clinical, Molecular, and Socio-economic characteristics of Hispanics and non-Hispanic patients with Acute Myeloid Leukemia in The California s Central Valley |
| Haifaa Abdulhaq, MD | | Evaluating the prevalence of targeted mutations in metastatic hormone positive breast cancer in a single institution of central valley California |
| Haifaa Abdulhaq, MD | | Single Institution Review of Castleman Disease: Case Series data |
| Haifaa Abdulhaq, MD | Britz Research Award | Genomic profile of Primary Central Nervous System Lymphoma in Central Valley |
| Haifaa Abdulhaq, MD | | High-Risk Genetic Profiles in Minorities with Multiple Myeloma |
| Haifaa Abdulhaq, MD | | Early Metabolic Changes During Induction Chemotherapy as Predictors of Minimal Residual Disease Status in Adult Acute Lymphoblastic Leukemia |
| Mohammed Bukari, MD | Alliance for Clinical Trials in Oncology | A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL |
| Mohammed Bukari, MD | Novartis Pharmaceuticals | A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (VAYHIT1) |
| Mohammed Bukari, MD | AbbVie Inc | A Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination With Obinutuzumab or Acalabrutinib With Different Ramp- Up Periods in Previously Untreated Subjects With CLL |
| Mohammed Bukari, MD | | Clinical and Molecular Profile of Patients with Essential Thrombocytosis (ET) in the Central Valley of California |
| Mohammed Bukari, MD | | Clinical Characteristics and Treatment Responses of Patients with Acute ITP Treated at Community Medical Center |
| Mohammed Bukari, MD | University of California, San Francisco | A Phase II Study, Evaluating the Efficacy of Montelukast in Reducing the Incidence and Severity of Monoclonal Antibodies Associated Infusion Reactions |
| Mohammed Bukari, MD | | Clinicopathologic and Genetic profile of Philadelphia Chromosome like (Ph-like) Acute B cell lymphocytic Leukemia inthe Central Valley |
| Mohammed Bukari, MD | | Quality Improvement Project to Improve Daratumumab Interference with Blood Compatibility Testing |
| Mohammed Bukari, MD | | Quality Improvement Project: Optimization of Heparin-induced Thrombocytopenia Testing and Management |
| Mohammed Bukari, MD | | Transfusion related complications in Sickle Cell Anemia |
| Mohammed Bukari, MD | | Sickle Cell Disease Quality of Life and Quality of Care Survey |
| Uzair Chaudhary, MD | Alliance for Clinical Trials in Oncology | A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy |
| Uzair Chaudhary, MD | National Cancer Institute (NCI) | Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair |
| Uzair Chaudhary, MD | National Cancer Institute (NCI) | PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE] |
| Uzair Chaudhary, MD | National Cancer Institute (NCI) | Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) |
| Uzair Chaudhary, MD | Alliance for Clinical Trials in Oncology | A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer |
| Uzair Chaudhary, MD | National Cancer Institute (NCI) | A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer |
| Uzair Chaudhary, MD | ECOG-ACRIN Cancer Research Group | A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients With Treatment Naïve Metastatic Pancreatic Cancer (GIANT) |
| Uzair Chaudhary, MD | NRG Oncology | A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer |
| Uzair Chaudhary, MD | National Cancer Institute (NCI) | Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial |
| Uzair Chaudhary, MD | SWOG Cancer Research Network | Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer |
| Uzair Chaudhary, MD | SWOG Cancer Research Network | A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES) |
| Uzair Chaudhary, MD | National Cancer Institute (NCI) | A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer |
| Uzair Chaudhary, MD | Mirati Therapeutics, Inc | A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy |
| Uzair Chaudhary, MD | Bristol-Myers Squibb Company | A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors |
| Uzair Chaudhary, MD | Genentech, Inc. | CO44668: A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma |
| Uzair Chaudhary, MD | | Demographic Variation in prevalence of genetic mutations in Stage IV Colon Cancer patients |
| Uzair Chaudhary, MD | | Evaluating the Clinical Utility of Circulating Tumor DNA as a Marker for Surveillance in Patients with Early-Stage Rectal Cancer |
| William Silveira, MD | NSABP Foundation Inc | A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy |
